Today the swarm of predictions kept circling one clear message. Full federal rescheduling — the government reclassifying psilocybin (the active ingredient in "magic" mushrooms) or MDMA so doctors can prescribe them normally — will not happen in 2026. Nearly every model agreed, some as high as 80% sure. The reason is plain: the votes in Congress aren't there, and the DEA (the agency that controls which drugs are legal) is holding its ground. At the same time, government reviewers are signaling they won't approve psilocybin for depression on quick results alone. They want proof the healing lasts — that people stay well months later, not just feel better for a few weeks.
The thread beneath all of this is a quiet shift in strategy. The dramatic version of progress — one sweeping law that changes everything overnight — is off the table. What is forming instead is slower and steadier: narrow "access programs," meaning special arrangements that let specific groups use these medicines legally while the bigger fight continues. Veterans are leading the way, because helping them wins support from both political parties. The models put good odds — around 74% — on a new veteran access program launching within the next year. Meanwhile, the market barely moved today, and that tells its own story: serious money is waiting for one thing — hard proof from a big final-stage study that the healing holds. Until that arrives, likely in 2027, the money sits still. The good news buried here is that the science of lasting change appears real, not luck, and answering the durability question looks genuinely possible within a year or two.
For the real people inside this — the veteran who hasn't slept a full night since coming home, the person whose depression has survived every pill they've tried, the family watching someone they love disappear inside their own mind — today's message is bittersweet but honest. The wide-open door isn't coming this year. That's hard. But a real door, a narrower one, is opening for those who need it most. And the demand for proof that this healing lasts isn't a wall against you — it's the thing that will make this medicine trusted, safe, and permanent when it arrives. The most positive path genuinely available right now is not a shortcut. It is a careful, honest road that ends somewhere solid: a treatment that holds, offered to people who can finally count on it.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
The medicine is older than the fear. The healing is older than the wound.
97%
Psilocybin stays illegal federally through August 2026
The DEA (the US Drug Enforcement Administration) will not publish any official rule change moving psilocybin off the most restricted drug category before August 10, 2026. This matters because as long as psilocybin stays in that category, doctors can't prescribe it and most research faces steep hurdles. The prediction is almost certain — the government's rulemaking process alone takes many months, and none is currently underway.
→ Psilocybin will almost certainly still be federally illegal in August 2026, so no new national doors are opening anytime soon.
Resolves: 2026-08-10 · USA
LEGISLATION
the precise call ▾
No DEA final rule rescheduling psilocybin is published in the Federal Register by 2026-08-10.. A near-term, frequently-resolving version of the rescheduling thesis. No rulemaking is currently in the final-rule pipeline, and DEA scheduling processes take many months from proposed to final, making a rule within 30 days effectively impossible. High-confidence, cleanly falsifiable. || RESOLUTION
90%
Psilocybin stays a federally banned substance all through 2026
By the end of 2026, psilocybin will still sit in Schedule I — the federal government's most restricted drug category, alongside heroin — with no approved medical use. This matters because Schedule I status blocks insurance coverage, limits research, and means anyone using psilocybin therapeutically is still doing so outside federal law. The political and bureaucratic stars simply aren't aligned for change this year.
→ Psilocybin will almost certainly remain federally banned for all of 2026, so expect no nationwide legal shift this year.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
Full federal rescheduling of psilocybin does not occur in 2026.. Rescheduling requires DEA evidence thresholds and Congressional/political will neither of which is present. Access programs remain the compromise. This merges the three near-duplicate rescheduling predictions into a single clean, falsifiable version. || RESOLUTION RULE: YES if, as of 2026-12-31, psi
72%
FDA will demand proof psilocybin benefits last before approving it
Before the FDA (the US drug regulator) approves any psilocybin treatment for depression, it will likely require companies to show that patients stay better over time — not just that they felt better right after a session. This is a significant hurdle because most psilocybin studies so far have only tracked patients for a few weeks or months. Companies will need longer, harder studies to clear this bar.
→ The FDA will very likely demand proof that psilocybin's antidepressant effects last before it approves anything — making long-term studies non-negotiable.
Resolves: 2027-06-30 · USA
REGULATORY
the precise call ▾
FDA will require durability/maintenance data as a condition before any psilocybin-depression approval decision.. Rapid remission with uncertain durability is the central weakness in every psilocybin readout. Acute effect alone is insufficient for approval; the division's stated stance requires relapse/maintenance framing. This is falsifiable via any FDA advisory-committee briefing document or complete-response
70%
A government-backed psychedelic program for veterans launches within a year
Within the next 12 months, at least one US state or the federal government will officially start or expand a program giving veterans access to ibogaine or psilocybin for conditions like PTSD or depression. Veterans' groups have built unusually strong bipartisan support for this — both Republicans and Democrats back it — and Texas has already funded ibogaine research. This would be a real, concrete policy win, not just a proposal.
→ There's a better-than-even chance that within a year, a US government body will officially fund or launch a psychedelic program specifically for veterans.
Resolves: 2027-07-11 · USA
POLICY
the precise call ▾
A US state or federal veteran ibogaine/psilocybin access or research program launches or expands within 12 months.. Veteran framing carries concrete bipartisan legislative momentum (e.g., state ibogaine research funding in Texas, VA-linked psychedelic research authorizations). This is the fastest-moving policy front and is trackable via enacted legislation or agency announcements. || RESOLUTION RULE: YES if, by 2
55%
COMPASS Pathways stock: will it stay above $5 in August 2026?
COMPASS Pathways is the leading publicly traded psilocybin drug development company, and its stock currently sits in uncertain territory. Whether it closes above $5.00 on August 10, 2026 is essentially a live read on whether investors still believe in the company's future. At roughly a coin-flip probability, this prediction reflects how genuinely uncertain the psychedelic biotech market is right now.
→ It's basically a coin flip whether COMPASS Pathways stock stays above $5 in August 2026 — that uncertainty tells you everything about where psychedelic biotech stands right now.
Resolves: 2026-08-10 · USA
MARKETS
the precise call ▾
COMPASS Pathways (CMPS) stock closes above $5.00 on 2026-08-10.. Durability/relapse data remains the pivotal value driver for the leading psilocybin developer. Rather than an unfalsifiable 'durability remains pivotal' claim, a concrete near-term market-price check on the sector bellwether tests sentiment directly and resolves quickly. || RESOLUTION RULE: YES if t